228 related articles for article (PubMed ID: 27067408)
1. Metabolic syndrome in prostate cancer: impact on risk and outcomes.
Karzai FH; Madan RA; Dahut WL
Future Oncol; 2016 Aug; 12(16):1947-55. PubMed ID: 27067408
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of androgen deprivation therapy.
Choi SM; Kam SC
Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
[TBL] [Abstract][Full Text] [Related]
4. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.
Collier A; Ghosh S; McGlynn B; Hollins G
Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430
[TBL] [Abstract][Full Text] [Related]
6. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
7. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
Leahy Y
Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms.
Tivesten Å; Pinthus JH; Clarke N; Duivenvoorden W; Nilsson J
Urol Oncol; 2015 Nov; 33(11):464-75. PubMed ID: 26141678
[TBL] [Abstract][Full Text] [Related]
10. The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy.
Morote J; Gómez-Caamaño A; Alvarez-Ossorio JL; Pesqueira D; Tabernero A; Gómez Veiga F; Lorente JA; Porras M; Lobato JJ; Ribal MJ; Planas J;
J Urol; 2015 Jun; 193(6):1963-9. PubMed ID: 25541340
[TBL] [Abstract][Full Text] [Related]
11. Emerging cardiometabolic complications of androgen deprivation therapy.
Choong K; Basaria S
Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
Basaria S
J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
[TBL] [Abstract][Full Text] [Related]
15. Metabolic complications of androgen deprivation therapy for prostate cancer.
Saylor PJ; Smith MR
J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628
[TBL] [Abstract][Full Text] [Related]
16. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Crawley D; Adolfsson J; Rudman S; Van Hemelrijck M
PLoS One; 2015; 10(3):e0117344. PubMed ID: 25794005
[TBL] [Abstract][Full Text] [Related]
17. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
18. Metabolic complications of androgen deprivation therapy for prostate cancer.
Saylor PJ; Smith MR
J Urol; 2009 May; 181(5):1998-2006; discussion 2007-8. PubMed ID: 19286225
[TBL] [Abstract][Full Text] [Related]
19. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
[TBL] [Abstract][Full Text] [Related]
20. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]